Occurrence of Nephrogenic Systemic Fibrosis with Group II Gadolinium-Based Contrast Agent in a Pediatric Oncology Patient with AKI

被引：0
|
作者：
Hanna, Christian [1 ]
Scheuermann, Amanda [2 ]
Hopp, Amanda M. [2 ]
Young, Kara [2 ]
Dillon, John J. [1 ]
Van Why, Scott K. [2 ]
机构：
[1] Mayo Clin Minnesota, Rochester, MN USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2021年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PO2018
引用
收藏
页码：620 / 620
页数：1
相关论文
共 50 条
  • [31] Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines
    Henrik S. Thomsen
    Sameh K. Morcos
    Torsten Almén
    Marie-France Bellin
    Michele Bertolotto
    Georg Bongartz
    Olivier Clement
    Peter Leander
    Gertraud Heinz-Peer
    Peter Reimer
    Fulvio Stacul
    Aart van der Molen
    Judith AW Webb
    European Radiology, 2013, 23 : 307 - 318
  • [32] Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines
    Thomsen, Henrik S.
    Morcos, Sameh K.
    Almen, Torsten
    Bellin, Marie-France
    Bertolotto, Michele
    Bongartz, Georg
    Clement, Olivier
    Leander, Peter
    Heinz-Peer, Gertraud
    Reimer, Peter
    Stacul, Fulvio
    van der Molen, Aart
    Webb, Judith A. W.
    EUROPEAN RADIOLOGY, 2013, 23 (02) : 307 - 318
  • [33] Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis - Reply
    Cheung, P. P. M.
    Raj, A. K. Dorai
    INTERNAL MEDICINE JOURNAL, 2007, 37 (07) : 509 - 509
  • [34] Advancing pharmacovigilance through analysis of a gadolinium-based contrast agent (GBCA) exposure dataset for nephrogenic systemic fibrosis: A RADAR report
    Nardone, Beatrice
    Laumann, Anne E.
    Edwards, Beatrice J.
    West, Dennis P.
    Belknap, Steven M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB5 - AB5
  • [35] Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging
    Giersig, C.
    RADIOLOGE, 2007, 47 (09): : 794 - 799
  • [36] Nephrogenic systemic fibrosis: A sufficient reason to avoid gadolinium-based contrast in all patients with renal impairment?
    Willicombe, Michelle
    Cunningham, John
    SEMINARS IN DIALYSIS, 2008, 21 (02) : 140 - 141
  • [37] Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media
    Canga, Ana
    Kislikova, Maria
    Martinez-Galvez, Maria
    Arias, Mercedes
    Fraga-Rivas, Patricia
    Poyatos, Cecilio
    de Francisco, Angel L. M.
    NEFROLOGIA, 2014, 34 (04): : 428 - 438
  • [38] A preclinical study to investigate the development of nephrogenic systemic fibrosis: A possible role for gadolinium-based contrast media
    Sieber, Martin A.
    Pietsch, Hubertus
    Walter, Jakob
    Haider, Wolfram
    Frenzel, Thomas
    Weinmann, Hanns-Joachim
    INVESTIGATIVE RADIOLOGY, 2008, 43 (01) : 65 - 75
  • [39] Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand
    Sieber, Martin A.
    Lengsfeld, Philipp
    Walter, Jakob
    Schirmer, Heiko
    Frenzel, Thomas
    Siegmund, Fred
    Weinmann, Hanns-Joachim
    Pietsch, Hubertus
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2008, 27 (05) : 955 - 962
  • [40] Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents
    Semelka, Richard C.
    Prybylski, John P.
    Ramalho, Miguel
    MAGNETIC RESONANCE IMAGING, 2019, 58 : 174 - 178
12345